Since medication abortion was first introduced in the United States (U.S.) in 2000, studies have consistently shown that it is safe and effective. Approximately 5% of medication abortion patients require additional medical intervention to complete the abortion, and <1% experience a serious adverse event. Despite this evidence, policy challenges to the availability of medication abortion continue, often driven by purported safety concerns.
During the COVID-19 pandemic, the U.S. Food and Drug Administration (FDA) removed an in person dispensing requirement for the first drug in the medication abortion regimen, mifepristone. These changes allowed for remote provision of medication abortion, including telehealth models that involve dispensing of abortion medications by mail. Research demonstrates that telehealth can increase abortion access, promote patient-centered care, and save costs while maintaining safety and effectiveness. However, these changes in clinical practice also introduce new challenges for researchers, including limited data sources and loss-to-follow-up. This dissertation investigates potential biases in research on the safety and effectiveness of simplified medication abortion care. It also offers recommendations for clinical practice, policy, and future research as these simplified models of abortion care expand, amid increasing state restrictions on abortion.
Paper 1 directly compares the safety and effectiveness of medication abortion provided with vs. without in-clinic screening tests (ultrasonography and pelvic exam) at 3 U.S. clinics. Paper 2 evaluates the impact of loss to follow-up on estimates of medication abortion safety and effectiveness by examining the outcomes of patients who were difficult to reach for follow-up. Paper 3 examines telehealth medication abortion patients’ follow-up care trajectories, including the reasons for, timing of, and locations of follow-up visits.